Investors have plowed another $130 million into a Series B to back the startup that’s led by Genentech vets, which brings its total raised to almost $350…

The late-stage skin condition biotech Novan is looking to batter ongoing headwinds and gun for a $60 million public offering.

Just two months after signing a CAR-T deal with Baylor, London-based Cell Medica has penned a new pact with University College London (UCL) to use its T-cell…

Promethera Biosciences is planning to IPO in April or May to raise €40 million for its pipeline of liver cell therapies.

A new deal from Novartis outlicenses its Phase II-ready, anti-PCSK9 antibody for a couple of inflammatory indications that include sepsis.

Gilead and Galapagos have hit go on a Phase III trial program for their rheumatoid arthritis drug, filgotinib.

Microcap Tokai has had a summer to forget, but its woes got worse this week as it announced that it will stop enrollment in one trial and ax another as its…

Perceptive Advisors has co-led a $14 million Series C financing to get startup Vyome into clinical testing with its lead candidate to treat antibiotic-…